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verall  outcomes  in  kidney  transplant  recipients  with
epatitis C  in a district  hospital  in Camagüey,  Cubavolución  general  de  receptores  de  trasplante  renal  con  hepatitis  C,
n  el  hospital  provincial  de  Camagüey,  Cuba
fusion and re-use of dialysers. Currently, the prevalence ofo the Editor,
nfection with the hepatitis C virus (HCV) is one of the main
roblems that can negatively affect the outcomes of renal
ransplant (RT).1 With new immunosuppressors, short-term
utcomes have improved. However, the longer-term prognosis
oes not run a parallel course and there is some disagreement
bout how to improve survival rates and outcomes in these
atients. These facts could be explained, at least partly, by
he barrier caused by HCV infection.2 In RT patients, HCV can
lter the course of liver disease and cast a shadow over the
rognosis of these patients.3
It has been reported that the primary cause of RT loss
n late stages is death in patients with a functioning graft,
hile death due to liver disease is, in almost all the reports,
etween the fourth and ﬁfth cause of death in this population.
enal recipients with HCV have been shown to have a higher
ncidence of severe opportunistic infections, post-transplant
iabetes mellitus, and glomerular diseases, including chronic
raft nephropathy. Liver failure is responsible for 8–28% of
eaths in the long-term in RT.1
It is known that 7–24% of RT recipients have biochemical
bnormalities in liver function. 50% of these abnormalities
rise from infection with hepatitis B virus, cytomegalovirus,
r Epstein–Barr virus; toxic processes due to drugs such as
zathioprine, mycophenolate mofetil, cyclosporine A, and
acrolimus; as well as alcohol abuse, haemosiderosis, and
eoplastic disease affecting the liver. The other 50% of liver
4isease in patients with a renal allograft is caused by HCV.
t is important to highlight that between 70% and 95% of
 Please cite this article as: Millet Torres D, Curbelo Rodríguez L, Ávila
e  receptores de trasplante renal con hepatitis C, en el hospital provinctransplant patients with HCV have active infection, probably
due to immunosuppressive treatment.
Infection with HCV is common in patients with end-stage
renal failure on haemodialysis, and the prevalence ranges
from 10% to 65%, depending on the geographic area. In France,
the prevalence is 10.4% of patients enrolled in dialysis pro-
grammes, while in the United States, Japan, and Italy, the
prevalence reaches 14%, 14.8%, and 20.6%, respectively.5 In
Spain, 30% of chronic renal patients awaiting RT of have pos-
itive hepatitis C virus antibodies (anti-HCV+). According to
the Spanish Registry of Chronic Graft Nephropathy, in recent
years, the prevalence of this infection has decreased sig-
niﬁcantly in transplant patients (6%), contributing to better
outcomes in the longer-term.6
In countries where infection is endemic (Egypt, Japan, and
counties in Southeast Asia), approximately 50% of the dialysis
population is infected. Even in countries with a low prevalence
of HCV, such as England and New Zealand, the rate ranges
between 3% and 5%, representing a rate 10 times higher than
that of the general population.7
In Latin America, the prevalence of HCV in haemodial-
ysis is variable. In Mexico, Brazil, and Colombia, it is 67%,
52%, and 53%, respectively. In Cuba, 52% of patients receiving
haemodialysis are HCV-positive.8 In the Haemodialysis unit
of the Hospital de Camagüey (Cuba), half of the patients are
infected with HCV at between 6 and 12 months after starting
haemodialysis. The most common risk factors are blood trans- Riopedre F, Benítez Méndez M, Prieto García F. Evolución general
ial de Camagüey, Cuba. Nefrologia. 2015;35:509–511.
HCV in haemodialysis is 58.66%, and in patients described as
suitable for RT, 63% have HCV acquired during haemodialysis.
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Table 1 – Distribution by age and sex. Renal Medicine Department, Hospital Universitario Manuel Ascunce Domenec,
Camagüey, 2011–2012.
Age group Male Female Total
N.◦ % N.◦ % N.◦ %
15–29 16 11.7 9 6.6 25 18.2
30–44 28 20.4 22 16.1 50 36.5
45–59 35 25.5 14  10.2 49  35.8
≥60 9 6.6 4  2.9 13 9.5
Total 88 64.2 49 35.8 137 100
Table 2 – Causes of loss of graft function. Renal Medicine Department, Hospital Universitario Manuel Ascunce Domenech,
Camagüey, 2011–2012.
HCV positive % HCV negative %
Died with functioning kidney 14 20.9 11 15.7
Acute rejection 13 19.4 10 14.3
Chronic graft dysfunction 10 14.9 8 11.4
Total 37 55.2 29 41.4
Table 3 – Main causes of mortality. Renal Medicine Department, Hospital Universitario Manuel Ascunce Domenech,
Camagüey, 2011–2012.
HCV positive % HCV negative %
Cardiovascular disease 13 19.4 9  12.8
Generalised sepsis 6 8.9 4 5.7
Chronic liver disease 3 4.5 1 1.4
Cerebrovascular disease 2 3.0 1 1.4
r
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8Total 26 
A cohort study was conducted to compare the gen-
eral outcomes of RT recipients with HCV acquired during
haemodialysis, against recipients without HCV, in the Renal
Medicine Department of the Hospital Universitario Manuel
Ascunce Domenech de Camagüey (Cuba), in the period from
01/2003 to 12/2012. This population comprises all patients who
have received RT, of which 137 patients who  met  the inclusion
criteria were taken as a sample (Table 1).
There was a high prevalence of HCV in the transplanted
population. There was an increased tendency to develop
post-transplant diabetes mellitus and acute rejection in HCV-
positive patients. Patient death and acute rejection were the
most common causes of loss of graft function. Cardiovascu-
lar disease and generalised sepsis were the most common
causes of death. In patients with HCV, graft and recipient sur-
vival were lower than in those without HCV. Most transplanted
patients were 30–40 years old and male (Tables 2 and 3).
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he evolution  of  occult  Hepati
mmunosuppression in  advan
volución  del  virus  de  la  hepatitis  
nfermedad  renal  crónica  avanzad
o the Editor,
epatitis C Virus (HCV) affects prognosis in patients with
dvanced chronic kidney disease (ACKD). A high prevalence of
lassic and occult HCV has been described in the haemodial-
sis population.1,2 Although we are in a new era of antiviral
reatment, there are no studies supporting the indication of
his therapy in patients with occult HCV infection yet. The
CKD population that is to receive future immunosuppres-
ion appears to be at risk for viral replication. Therefore,
t would bear considering pre-immunosuppression antiviral
reatment.3 There is just 1 published case on the subject,
lthough that patient did not have renal disease.4 This let-
er presents the clinical course of occult HCV in 2 patients
ith ACKD who  received immunosuppressive therapy. The
etermination of occult HCV was performed in la Fundación
ara el Estudio de las Hepatitis Virales (the Foundation for
he Study of Viral Hepatides), using ultracentrifugation of
erum5 and ultrasensitive PCR in the liver and in peripheral
lood mononuclear cells (PBMC).6 In recent years, the high-
ensitivity anti-HCV core antibody detection technique has
een added.7
ase  1 40-year-old woman, smoker, with systemic lupus erythe-
atosus, antiphospholipid syndrome, hypertension, tertiary
yperparathyroidism, osteoporosis, hyperhomocysteinaemia,
DOI of original article:
ttp://dx.doi.org/10.1016/j.nefro.2015.06.005.
 Please cite this article as: Martín-Gómez MA, Castillo-Aguilar I, Barr
abello-Díaz M. Evolución del virus de la hepatitis C oculto tras inmun
015;35:511–513.(5):509–516 511
2013-2514/© 2015 Sociedad Espan˜ola de Nefrología. Published
by Elsevier España, S.L.U. This is an open access article under
the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.nefroe.2015.02.006
 C Virus  after
d  CKD  patients
culto  tras  inmunosupresión  en
and hyperuricaemia. She began haemodialysis in 1990
(renal transplant from 1991 to 1998). Regular medications
were cinacalcet, aluminium hydroxide, calcium acetate, rise-
dronate, folic acid, multivitamin B1/B6/B12, omeprazole,
allopurinol, carvedilol, hydroxychloroquine, acenocoumarol,
iron, and intradialytic darbopoetin.
From March 2008, serial “indeterminate” results were
ascertained (ELISA, RIMA) for HCV (positive only for the NS3
fraction). Several retests were carried out, and cross-reaction
testing was performed for underlying autoimmune disease.
Despite normal blood transaminase levels, the possibility was
raised of occult HCV. This was conﬁrmed in peripheral blood
mononuclear cells (PBMC, 1170 copies/g total RNA), and in
the liver. Further investigations were performed: transjugu-
lar liver biopsy, showing chronic hepatitis grade/stage 0/0;
FibroScan®, 6.3 KPa; APRI, 0.81; and Forns score, 7.59. Poten-
tial external contamination was tested for, but did not occur:
viral PCR and serology were performed on the other patients
in the unit and the healthcare staff. No new cases of clas-
sic HCV infection were detected. In February 2009, the patient
received intravenous immunoglobulin IVIG (2 g/kg) for pre-
transplant desensitisation (in the end, transplant was not
performed, for other reasons), and from June to November
2009 she received azathioprine (AZT 50 mg/day) and corti-
coid therapy (GC 5 mg/day) for lupus activity. There was noil-Cuadrado G, Cabezas-Fernández T, Casado-Martín M,
osupresión en enfermedad renal crónica avanzada. Nefrologia.
there was an immune response (Fig. 1). In March and April
2009, there was a transient mild increase in ALT, with a maxi-
mum level of 42 UI/L.
